Robotic Versus Open Comparison in the Surgical Treatment of Wide Abdominal Wall heRnias (ROCSTAR) (ROCSTAR)

April 10, 2025 updated by: Filip Muysoms, Algemeen Ziekenhuis Maria Middelares

Robotic Versus Open Comparison in the Surgical Treatment of Wide Abdominal Wall Hernias: a Multicenter International Randomized Controlled Trial

In the treatment of ventral incisional hernias, a mesh repair in the retromuscular plane is considered as the gold standard. To allow for adequate medialization of the fascial borders and a complete closure of the defect in case of large incisional hernias, component separation techniques are increasingly being used. When compared to anterior component separation, posterior component separation by transversus abdominis release (TAR) seems to decrease postoperative wound problems. While laparoscopic techniques pose significant difficulties to perform TAR minimally invasively (mainly due to ergonomic and technical reasons), these limitations seem to be overcome by robotic platforms. Initial retrospective patient series report on significantly shorter postoperative hospital stay and fewer complications after robotic transversus abdominis release (rTAR), when compared to open transversus abdominis release (oTAR). High-quality prospective evidence on rTAR is currently lacking.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- All patients requiring treatment of a wide ventral incisional hernia (of more than 8 centimetres in width)

Exclusion Criteria:

  • Pregnant or suspected pregnancy
  • Not-curatively treated malignancy, with life expectancy less than 24 months
  • Patients unable to give informed consent or complete study specific questionnaires
  • Emergency surgery
  • Primary ventral hernia repair
  • Exclusively lateral hernias not involving the midline
  • Incisional hernia repair after open abdomen or enterocutaneous fistula
  • Active wound infection
  • Previous anterior or posterior component separation
  • Patients with an existing ostomy
  • Patients with a life expectancy of less than 24 months
  • Patients suspected of being unable to comply with the study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: rTAR
Patients randomized in the robotic group will undergo the technique for intra-and perioperative management for robotic complex abdominal wall repair cases as used in the center. A robotic surgical platform (da Vinci X or da Vinci Xi Surgical System, Intuitive Surgical, Aubonne, Switzerland) will be used and a retrorectus +/- retromuscular mesh placement performed. Use of component separation or not will be at the discretion of the surgeon. In principle the posterior layer and the anterior fascia will be closed avoiding a bridging technique. Drain management and mesh fixation are left to the surgeon's preference.
Incisional hernia repair for the treatment of wide ventral incisional hernias.
Active Comparator: oTAR
Patients randomized in the open group will undergo the technique for intra-and perioperative management for open complex abdominal wall repair cases as used in the center. A retrorectus +/- retromuscular mesh placement performed. Use of component separation or not will be at the discretion of the surgeon. In principle the posterior layer and the anterior fascia will be closed avoiding a bridging technique. Drain management and mesh fixation are left to the surgeon's preference.
Incisional hernia repair for the treatment of wide ventral incisional hernias.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of postoperative hospital stay
Time Frame: hours from the end of surgery (last skin suture) until discharge, assessed up to 20 days
Length of postoperative hospital stay
hours from the end of surgery (last skin suture) until discharge, assessed up to 20 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reoperation rate
Time Frame: 30 days
Reoperation rate
30 days
Skin-to-skin operative time
Time Frame: Per-operative (minutes)
Skin-to-skin operative time from first incision until last skin suture
Per-operative (minutes)
Conversion rate
Time Frame: Per-operative
Conversion rate from the robotic-assisted approach to the open approach
Per-operative
Surgical site related complications
Time Frame: 30 days
Surgical site infection - surgical site occurrence - surgical site occurrence requiring procedural interventions
30 days
Readmission rate
Time Frame: 30 Days and 3 months postoperative
Readmission rate
30 Days and 3 months postoperative
Post-anesthetic discharge scoring system
Time Frame: From the end of surgery (last skin suture) until discharge, assessed up to 20 days
Minimum score is 0, maximum score is 12. The higher the score, the better the outcome.
From the end of surgery (last skin suture) until discharge, assessed up to 20 days
Postoperative visual analogue scale pain score
Time Frame: From the end of surgery (last skin suture) until discharge, assessed up to 20 days
Minimum score is 0, maximum score is 10. The higher the score, the worse the outcome.
From the end of surgery (last skin suture) until discharge, assessed up to 20 days
EuraHS Quality of Life Scoring
Time Frame: Preoperatively, 30 days, 3 months, 12 months, 24 months, 60 months
Minimum score is 0, maximum score is 90. The higher the score, the worse the outcome.
Preoperatively, 30 days, 3 months, 12 months, 24 months, 60 months
Body Image Scale
Time Frame: Preoperatively, 30 days, 3 months, 12 months, 24 months, 60 months
Minimum score is 0, maximum score is 10. A higher score means a higher level of body image disturbance (worse outcome).
Preoperatively, 30 days, 3 months, 12 months, 24 months, 60 months
Hernia recurrence
Time Frame: 30 days, 3 Months, 12 months, 24 months, 60 months
Hernia recurrence
30 days, 3 Months, 12 months, 24 months, 60 months
Reoperation for hernia recurrence or abdominal surgery not for hernia recurrence
Time Frame: 30 days, 3 Months, 12 months, 24 months, 60 months
Reoperation for hernia recurrence or abdominal surgery not for hernia recurrence
30 days, 3 Months, 12 months, 24 months, 60 months
Postoperative complications
Time Frame: 30 days
Postoperative complications classified acoording to the Clavien-Dindo Classification
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Filip Muysoms, MD PhD, Clinical research center Maria Middelares

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2025

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2033

Study Registration Dates

First Submitted

April 2, 2022

First Submitted That Met QC Criteria

October 8, 2022

First Posted (Actual)

October 12, 2022

Study Record Updates

Last Update Posted (Actual)

April 11, 2025

Last Update Submitted That Met QC Criteria

April 10, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Abdominal Wall Hernia

Clinical Trials on incisional hernia repair

Subscribe